862PRetrospective evaluation of neutropenic admission events in metastatic or high-risk hormone-sensitive prostate cancer (HSPC) patients having docetaxel chemotherapy upfront or for castrate-resistant prostate cancer (CRPC) in STAMPEDE
Mintz, H P, Amos, C, Brannan, R, Brawley, C, Calvert, J, Gannon, M R, Hounsome, L, Ingleby, F C, McPhail, S, Parmar, M K B, Parsons, H M, Patel, P, Rauchenberger, M, Sydes, M R, Wu, H, James, N DVolume:
30
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdz248.019
Date:
October, 2019
File:
PDF, 82 KB
2019